Results 111 to 120 of about 196,807 (276)
Plasticity changes of molecular networks form a cellular learning process. Signaling network plasticity promotes cancer, metastasis, and drug resistance development. 55 plasticity‐related cancer drug targets are listed (20 having already approved drugs, 9 investigational drugs, and 26 being drug target candidates).
Márk Kerestély +5 more
wiley +1 more source
ABSTRACT Background Pancreatectomy for pancreatic ductal adenocarcinoma (PDAC) with arterial abutment is a complex, high‐risk surgery. We aimed to investigate the clinicopathological features, risk factors, and learning curve for local recurrence after pancreatectomy for PDAC with arterial abutment.
Jun Ishida +9 more
wiley +1 more source
We systematically reviewed conversion therapy for esophageal squamous cell carcinoma and propose a response‐based treatment strategy for cT4b and M1 disease. For cT4b, we emphasize definitive chemoradiotherapy with timed re‐evaluation and selective salvage or chemoselection to surgery; for M1, conversion is reserved for limited‐burden responders with ...
Eisuke Booka, Hiroya Takeuchi
wiley +1 more source
ABSTRACT Background Radical gastrectomy, followed by adjuvant chemotherapy has been a common practice in Japan for peritoneal lavage cytology‐positive (CY1) but peritoneal dissemination‐negative (P0) stage IV gastric cancer. This study aimed to clarify the differences in treatment outcomes between upfront surgery and preoperative chemotherapy, followed
Kenichiro Furukawa +12 more
wiley +1 more source
3D Hydrogel Cell Cultures and Their Biomedical Applications
The review highlights the advantages of hydrogel‐based 3D cell cultures over traditional 2D models. These hydrogels closely mimic natural cellular environments, improving research in tissue engineering, drug discovery, cancer studies, and neuroscience.
Tri Lan Thai +7 more
wiley +1 more source
Aims In the AEGEAN study, perioperative durvalumab plus platinum‐based neoadjuvant chemotherapy for patients with resectable stage II to IIIB (N2) non‐small‐cell lung cancer (NSCLC) demonstrated a favourable benefit–risk profile. This study evaluated population pharmacokinetics (PopPK) and exposure–response (ER) relationships of durvalumab in patients ...
Xiaoying Zhao +12 more
wiley +1 more source
Abstract Aims This study aimed to develop and validate a population pharmacokinetic‐pharmacodynamic (pop‐PK‐PD) model to describe carboplatin‐induced myelosuppression in cancer patients and support dose individualization. Methods Data from 580 cancer patients treated with carboplatin at Amsterdam UMC between 2019 and 2022 were used for model ...
Alessandro De Carlo +10 more
wiley +1 more source
MicroRNA-7 sensitizes non-small cell lung cancer cells to paclitaxel
Ronghua Liu +10 more
openalex +2 more sources

